Correlation Between Infant Bacterial and Zinzino AB

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Infant Bacterial and Zinzino AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Infant Bacterial and Zinzino AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Infant Bacterial Therapeutics and Zinzino AB Series, you can compare the effects of market volatilities on Infant Bacterial and Zinzino AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Infant Bacterial with a short position of Zinzino AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Infant Bacterial and Zinzino AB.

Diversification Opportunities for Infant Bacterial and Zinzino AB

-0.43
  Correlation Coefficient

Very good diversification

The 3 months correlation between Infant and Zinzino is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Infant Bacterial Therapeutics and Zinzino AB Series in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zinzino AB Series and Infant Bacterial is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Infant Bacterial Therapeutics are associated (or correlated) with Zinzino AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zinzino AB Series has no effect on the direction of Infant Bacterial i.e., Infant Bacterial and Zinzino AB go up and down completely randomly.

Pair Corralation between Infant Bacterial and Zinzino AB

Assuming the 90 days trading horizon Infant Bacterial is expected to generate 4.2 times less return on investment than Zinzino AB. In addition to that, Infant Bacterial is 1.59 times more volatile than Zinzino AB Series. It trades about 0.02 of its total potential returns per unit of risk. Zinzino AB Series is currently generating about 0.1 per unit of volatility. If you would invest  2,477  in Zinzino AB Series on August 29, 2024 and sell it today you would earn a total of  5,953  from holding Zinzino AB Series or generate 240.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Infant Bacterial Therapeutics  vs.  Zinzino AB Series

 Performance 
       Timeline  
Infant Bacterial 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Infant Bacterial Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Zinzino AB Series 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Zinzino AB Series are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Zinzino AB may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Infant Bacterial and Zinzino AB Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Infant Bacterial and Zinzino AB

The main advantage of trading using opposite Infant Bacterial and Zinzino AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Infant Bacterial position performs unexpectedly, Zinzino AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zinzino AB will offset losses from the drop in Zinzino AB's long position.
The idea behind Infant Bacterial Therapeutics and Zinzino AB Series pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes